Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
UZEDY: Information from Industry
View All
conference coverage
Xanomeline-Trospium Data Presented at Psych Congress and NEI
NEI Congress 2025
news
Sustained Symptom Improvement Across Domains With Long-Term Xanomeline–Trospium Treatment
November 25, 2025
One year of xanomeline–trospium treatment sustained improvements across all schizophrenia symptom domains in EMERGENT-4. Patients switching from placebo caught up within just 4 weeks.
news
Impact of Dose and Titration Speed on the Tolerability of Xanomeline–Trospium in Schizophrenia
November 25, 2025
Faster xanomeline–trospium titration to 125 mg/30 mg twice daily improved tolerability versus slower dosing, challenging start low go slow assumptions.
news
Low Rates of Extrapyramidal Symptoms With Long-Term Xanomeline–Trospium Treatment in Schizophrenia
November 25, 2025
EMERGENT-4 data show xanomeline–trospium maintained low EPS rates through 52 weeks with no parkinsonism or akathisia, distinguishing it from dopamine blockers.
Psych Congress 2025
news
Stable Outcomes Seen in Transition to Xanomeline-Trospium Therapy for Schizophrenia
October 28, 2025
Patients with stable schizophrenia can switch to xanomeline–trospium without symptom worsening, highlighting a new treatment option with a novel mechanism.
news
Real-World Transition Strategies for Initiating Xanomeline–Trospium in Schizophrenia
October 28, 2025
Clinicians are using gradual cross-titration when switching to xanomeline–trospium for schizophrenia, achieving symptom control with manageable side effects.
news
Phase 4 Trial Examines Effects of Food on Xanomeline–Trospium Safety and Efficacy in Schizophrenia
October 28, 2024
After a 4-week acclimation period, patients with schizophrenia maintained symptom stability when switching xanomeline–trospium dosing from fasting to fed conditions.
